Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results
Molecular Partners (SIX: MOLN; NASDAQ: MOLN) announced CEO Patrick Amstutz will present at two investor conferences in March 2026 and that the company will release its full-year 2025 financial results and Annual Report on March 12, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Molecular Partners (SIX: MOLN; NASDAQ: MOLN) announced CEO Patrick Amstutz will present at two investor conferences in March 2026 and that the company will release its full-year 2025 financial results and Annual Report on March 12, 2026.
Fireside chats at TD Cowen (March 2) and Leerink Partners (March 9) will be available on the company investor website. The results release is scheduled for March 12 at 4:00 pm EDT (9:00 pm CET).
Details
News Market Reaction – MOLN
On Feb 26, the day this news came out, MOLN closed 3.37% below the previous close.
Data tracked by StockTitan Argus for the Feb 26 session.
Key Figures
- TD Cowen conference
- 46th Annual
- TD Cowen 46th Annual Health Care Conference reference
- TD Cowen dates
- March 2-4, 2026
- Conference dates for TD Cowen Health Care event
- TD Cowen fireside time
- 2:30-3:00 pm ET
- Scheduled time for March 2 fireside chat
- Leerink dates
- March 9-11, 2026
- Conference dates for Leerink Partners Global Healthcare Conference
- Leerink fireside time
- 4:20-4:50 pm EDT
- Scheduled time for March 9 fireside chat
- FY 2025 results date
- March 12, 2026
- Planned release date for full-year 2025 financial report
- Results call time
- 4:00 pm EDT
- Scheduled time for full-year 2025 financial results announcement
Previous Earnings Reports
-
H1 2025 results, MP0533 progress, MP0712 advancing, runway extension and workforce cuts.
-
Q1 2025 results, strong cash, expanded Orano Med partnership and MP0533 progress.
-
Q4 and FY 2024 results with pipeline progress and improved loss metrics.
-
Q1 2024 update on advancing pipeline, cash position and 2024 expense guidance.
-
Q4 2023 and full-year 2023 financial and corporate highlights.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
darprin therapeutics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced its attendance and presentations at upcoming investor conferences.
Molecular Partners will also issue its full-year 2025 financial report, along with its Annual Report, on March 12, 2026.
Details of the events:
TD Cowen 46th Annual Health Care Conference
Boston, MA, March 2-4, 2026
Molecular Partners CEO Patrick Amstutz will take part in a fireside chat on Monday, March 2 at 2.30-3.00 pm ET (8.30-9.00 pm CET).
Leerink Partners Global Healthcare Conference 2026
Miami, FL, March 9-11 March, 2026
Molecular Partners CEO Patrick Amstutz will take part in a fireside chat on Monday, March 9 at 4.20-4.50 pm EDT (9.20-9.50 pm CET).
Full Year 2025 Financial Results Announcement
Thursday, March 12, 2026 at 4.00 pm EDT (9.00 pm CET).
Both fireside chats will be made available on the Company’s website under the investor section.
About Molecular Partners AG
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs
For further details, please contact:
Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361
Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners’ product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners’ collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners’ expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as “aim”, "anticipate", “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and similar expressions, and are based on Molecular Partners’ current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include, but are not limited to, those set forth in under the heading “Risk Factors” in Molecular Partners’ Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners’ website at www.molecularpartners.com.
Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.